ANGELA RAMSEY: Open Payments
NPI 1558919365 · TEXARKANA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$435 in 37 payments from 9 companies in 2025. Trend: 2023 $480 · 2024 $506 · 2025 $435
Food & beverage: $435
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $143 |
| PFIZER INC. | 5 | $85 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| Lilly USA, LLC | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: ELIQUIS, UBRELVY, CONTRAVE, MOUNJARO, VRAYLAR, REXULTI, QULIPTA, Auvelity.
Industry payments across AR — which companies pay providers there.
